Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
March 08 2023 - 8:51AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating small molecule drugs
for viral infections, today announced that data for EDP-235, its
lead 3CL protease inhibitor in development as an oral, once-daily
treatment for COVID-19, will be presented at the 36th International
Conference on Antiviral Research (ICAR) being held March 13-17,
2023 at the Centre De Congres De Lyon (Lyon Convention Center) in
Lyon, France.
New clinical data being highlighted include results from a Phase
1 study of EDP-235. Additionally, new preclinical findings
regarding EDP-235’s effect on replication and transmission, as well
as its potential to mitigate viral rebound, will be presented.
Oral Presentation:
Date/Time: Wednesday, March 15 from 8:30 – 11:30 am Central
European Time (CET) Session Name: Influenza, RSV, and Other
Respiratory Viruses – Short Presentations Abstract ID#: 021
Title: “EDP-235, an Oral 3CL Protease Inhibitor for the
Treatment of COVID-19, Suppresses Viral Replication and Spread in
SARS-CoV-2-Infected Ferrets” Presenter Name: Michael Rhodin,
Ph.D.
Poster Presentations:
Date/Time: Tuesday, March 14 from 5 – 6pm and Wednesday,
March 15 from 2:15 – 3:15 pm CET Abstract ID#: 523
Title: “EDP-235, a Potent, Once-daily, Oral Antiviral,
Demonstrates Excellent Penetration into SARS-CoV-2 Target Tissues,
with the Potential for Mitigation of Viral Rebound in COVID-19
Patients” Presenter: Indy Zhang, Ph.D.
Date/Time: Tuesday, March 14 from 6 – 7pm and Wednesday,
March 15 from 12:15 – 1:15 pm CET Abstract ID#: 524
Title: “EDP-235, an Oral, Once Daily, Ritonavir-Free, 3CL
Protease Inhibitor for the Treatment of COVID-19: Results from
Phase 1 Study in Healthy Subjects” Presenter: Guy De La
Rosa, M.D.
Date/Time: Tuesday, March 14 from 6 – 7pm and Wednesday,
March 15 from 12:15 – 1:15 pm CET Abstract ID#: 528
Title: “High Throughput Screen to Identify Non-Nucleoside
Small Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA
Polymerase” Presenter: Tessa Cressey, Ph.D.
Posters will be available to view on the conference platform
during the conference. Further information about ICAR 2023 can be
found here.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections. Enanta’s research and development programs include
clinical candidates for the following disease targets: respiratory
syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus
(HBV). Enanta is also conducting research on a single agent
targeting both RSV and human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is part of one of the leading treatment
regimens for curing chronic HCV infection and is sold by AbbVie in
numerous countries under the tradenames MAVYRET® (U.S.) and
MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit
www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230308005528/en/
Media and Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024